Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
GBA3
Introduction
Cytosolic beta-glucosidase, also known as cytosolic beta-glucosidase-like protein 1, is a beta-glucosidase (EC 3.2.1.21) enzyme that in humans is encoded by the GBA3 gene.[1][2]
Function
Function
Cytosolic beta-glucosidase is a predominantly liver enzyme that efficiently hydrolyzes beta-D-glucoside and beta-D-galactoside, but not any known physiologic beta-glycoside, suggesting that it may be involved in detoxification of plant glycosides.[2] GBA3 also has significant neutral glycosylceramidase activity (EC 3.2.1.62), suggesting that it may be involved in a non-lysosomal catabolic pathway of glucosylceramide metabolism.[3]
See also
See also
References
References
- ↑ “Entrez Gene: glucosidase”.
- ↑ 2.0 2.1 de Graaf M, van Veen IC, van der Meulen-Muileman IH, Gerritsen WR, Pinedo HM, Haisma HJ (June 2001). “Cloning and characterization of human liver cytosolic beta-glycosidase”. Biochem. J. 356 (Pt 3): 907–10. doi:10.1042/0264-6021:3560907. PMC 1221920. PMID 11389701.
- ↑ Hayashi Y, Okino N, Kakuta Y, Shikanai T, Tani M, Narimatsu H, Ito M (October 2007). “Klotho-related protein is a novel cytosolic neutral beta-glycosylceramidase”. J. Biol. Chem. 282 (42): 30889–900. doi:10.1074/jbc.M700832200. PMID 17595169.
Further reading
Further reading
- Bolmstedt A, Sjölander S, Hansen JE, Akerblom L, Hemming A, Hu SL, Morein B, Olofsson S (July 1996). “Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response”. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12 (3): 213–20. doi:10.1097/00042560-199607000-00001. PMID 8673525.
- Beutler E, Beutler L, West C (2004). “Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher disease”. J. Lab. Clin. Med. 144 (2): 65–8. doi:10.1016/j.lab.2004.03.013. PMID 15322500.
- Yahata K, Mori K, Arai H, et al. (2000). “Molecular cloning and expression of a novel klotho-related protein”. J. Mol. Med. 78 (7): 389–94. doi:10.1007/s001090000131. PMID 11043382.
- Pantophlet R, Wilson IA, Burton DR (2003). “Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design”. J. Virol. 77 (10): 5889–901. doi:10.1128/JVI.77.10.5889-5901.2003. PMC 154011. PMID 12719582.
- Tribolo S, Berrin JG, Kroon PA, et al. (2007). “The crystal structure of human cytosolic beta-glucosidase unravels the substrate aglycone specificity of a family 1 glycoside hydrolase”. J. Mol. Biol. 370 (5): 964–75. doi:10.1016/j.jmb.2007.05.034. PMID 17555766.
- Noguchi J, Hayashi Y, Baba Y, et al. (2008). “Crystal structure of the covalent intermediate of human cytosolic beta-glucosidase”. Biochem. Biophys. Res. Commun. 374 (3): 549–52. doi:10.1016/j.bbrc.2008.07.089. PMID 18662675.
- Berrin JG, Czjzek M, Kroon PA, et al. (2003). “Substrate (aglycone) specificity of human cytosolic beta-glucosidase”. Biochem. J. 373 (Pt 1): 41–8. doi:10.1042/BJ20021876. PMC 1223474. PMID 12667141.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). “Construction and characterization of a full length-enriched and a 5′-end-enriched cDNA library”. Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
- Wolk T, Schreiber M (2006). “N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization”. Med. Microbiol. Immunol. 195 (3): 165–72. doi:10.1007/s00430-006-0016-z. PMID 16547752.
- Papandreou MJ, Fenouillet E (1997). “Effect of various glycosidase treatments on the resistance of the HIV-1 envelope to degradation”. FEBS Lett. 406 (1–2): 191–5. doi:10.1016/S0014-5793(97)00273-1. PMID 9109416.
- Dekker N, Voorn-Brouwer T, Verhoek M, et al. (2010). “The cytosolic beta-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation”. Blood Cells Mol. Dis. 46 (1): HASH(0x26e7390). doi:10.1016/j.bcmd.2010.07.009. PMIDÂ 20728381.
- Berrin JG, McLauchlan WR, Needs P, et al. (2002). “Functional expression of human liver cytosolic beta-glucosidase in Pichia pastoris. Insights into its role in the metabolism of dietary glucosides”. Eur. J. Biochem. 269 (1): 249–58. doi:10.1046/j.0014-2956.2001.02641.x. PMID 11784319.
- Feizi T, Larkin M (1990). “AIDS and glycosylation”. Glycobiology. 1 (1): 17–23. doi:10.1093/glycob/1.1.17. PMID 2136376.
- Németh K, Plumb GW, Berrin JG, et al. (2003). “Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans”. Eur J Nutr. 42 (1): 29–42. doi:10.1007/s00394-003-0397-3. PMID 12594539.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). “The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)”. Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2002). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Land A, Braakman I (2001). “Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum”. Biochimie. 83 (8): 783–90. doi:10.1016/S0300-9084(01)01314-1. PMID 11530211.
- Hart ML, Saifuddin M, Spear GT (2003). “Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin”. J. Gen. Virol. 84 (Pt 2): 353–60. doi:10.1099/vir.0.18734-0. PMID 12560567.